Literature DB >> 28167540

Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.

Maryam Mahmood1, Omar Abu Saleh2, M Rizwan Sohail2.   

Abstract

Entities:  

Keywords:  fungal infections; infectious disease

Mesh：

Substances：

Year:  2017        PMID： 28167540      PMCID： PMC5365687          DOI： 10.1128/AAC.00019-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  4 in total

1.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

2.  Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Authors:  Urshila Durani; Pritish K Tosh; Jason N Barreto; Lynn L Estes; Paul J Jannetto; Aaron J Tande
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  Suspected posaconazole toxicity in a pediatric oncology patient.

Authors:  Jessica Martino; Brian T Fisher; Kristopher R Bosse; Rochelle Bagatell
Journal:  Pediatr Blood Cancer       Date:  2015-05-06       Impact factor: 3.167
  4 in total
  7 in total

1.  Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.

Authors:  Travis Wassermann; Eleanor K Reimer; Marie McKinnon; Wendy Stock
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia.

Authors:  George R Thompson; Diana Chang; Rebecca R Wittenberg; Ian McHardy; Alison Semrad
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Posaconazole-Induced Pseudohyperaldosteronism.

Authors:  Kevin Kuriakose; Whitney J Nesbitt; Matthew Greene; Bryan Harris
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.

Authors:  Huan-Huan Ji; Xue-Wen Tang; Ni Zhang; Ben-Nian Huo; Ying Liu; Lin Song; Yun-Tao Jia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

5.  Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.

Authors:  Minh-Vu H Nguyen; Matthew R Davis; Rebecca Wittenberg; Ian Mchardy; John W Baddley; Brian Y Young; Alex Odermatt; George R Thompson
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

6.  Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.

Authors:  Charlotte Boughton; David Taylor; Lea Ghataore; Norman Taylor; Benjamin C Whitelaw
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-02-09

7.  Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole.

Authors:  Maria Dolores Sanchez-Niño; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2018-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.